ORGS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.27 -- higher than merely 5.07% of US-listed equities with positive expected earnings growth.
With a year-over-year growth in debt of -32.64%, Orgenesis Inc's debt growth rate surpasses merely 8.77% of about US stocks.
In terms of twelve month growth in earnings before interest and taxes, Orgenesis Inc is reporting a growth rate of 295.98%; that's higher than 95.27% of US stocks.
If you're looking for stocks that are quantitatively similar to Orgenesis Inc, a group of peers worth examining would be BGMD, XXII, ADMP, HCAT, and DMRC.
ORGS's SEC filings can be seen here. And to visit Orgenesis Inc's official web site, go to www.orgenesis.com.
Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. The company was founded in 2008 and is based in Germantown, Maryland.
Annual Russell indexes reconstitution captures the 4,000 largest US stocks, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.
Orgenesis (ORGS) has entered into a preliminary, non-binding term sheet with Leidos (LDOS), to develop, and potentially obtain FDA marketing approval of Orgenesis’ Ranpirnase for the treatment of patients with SARS-CoV-2, the virus that causes COVID-19.Ranpirnase, a broad spectrum anti-viral agent was recently acquired from Tamir Biotech. Ranpirnase has already demonstrated a...
Orgenesis recently acquired the assets of Tamir Biotechnology, Inc., including Ranpirnase, a broad spectrum anti-viral agent. Ranpirnase catalyzes the degradation of RNA, and mediates several essential biological activities, including the regulation of cell proliferation, maturation, differentiation, and cell death.
The goal of the BioShield Program is to increase the level of preparedness to fight against emerging outbreaks and help avoid a global pandemic. Orgenesis plans to leverage its POCare anti-viral technologies as part of the development efforts of the BioShield Program, including exploration of alternative and breakthrough processes to induce neutralizing antibody discovery and validation against targeted pathogens.
Under the agreement, the parties will conduct a clinical study with a goal of utilizing and validating a number of Orgenesis’ proprietary POCare Technologies, including a novel, automated cell culturing system, designed to enable a faster, safer and metabolically optimized culturing and expansion process for the generation and expansion tumor infiltrating lymphocytes (TIL) for use in adoptive T-cell therapies. The goal of the cell culturing system is to provide an innovative and simplified method for TIL generation and expansion in an automated and controlled system from the initial TIL production to final product with minimal human operation.